Second-quarter results exceeded the prior guidance, prompting an upward revision to the full-year forecast. Revenue is revised to 565,000 million yen, core operating profit to 105,000 million yen, operating profit to 104,000 million yen, and net income attributable to owners of the parent to 94,000 million yen. Foreign exchange assumptions were also revised.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4506","jir_company_name":"Sumitomo Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4506-20261030-03.pdf","jir_short_summary":"Second-quarter results exceeded the prior guidance, prompting an upward revision to the full-year forecast. Revenue is revised to 565,000 million yen, core operating profit to 105,000 million yen, operating profit to 104,000 million yen, and net income attributable to owners of the parent to 94,000 million yen. Foreign exchange assumptions were also revised.","jir_summary":"### Summary of Forecast Revisions\nSumitomo Pharma Co., Ltd. has upwardly revised its full-year consolidated earnings guidance following second-quarter results that exceeded the previously announced guidance. Revenue for the interim period increased to 266,500 million yen, core operating profit to 42,100 million yen, operating profit to 42,300 million yen, and interim net income attributable to owners of the parent to 38,200 million yen. Considering foreign exchange effects, the full-year exchange rate assumption has been revised to 1 USD = 157 yen.\n\n### Outlook and Impact for Investors\nAs a result of this revision, sales growth is expected to proceed as assumed, which may have a positive effect on shareholder returns and investment decisions. Investors should monitor foreign exchange volatility, new drug and therapeutic sales trends, and SG&A expense developments, as these factors could materially affect future performance.","jir_financial_highlights":"Revenue: 2,665,000 million yen (vs. previous guidance +155,000 million yen)\nCore Operating Profit: 421,000 million yen (vs. previous guidance +121,000 million yen)\nOperating Profit: 423,000 million yen (vs. previous guidance +123,000 million yen)\nInterim Net Income Attributable to Owners of the Parent: 382,000 million yen (vs. prior period +122,000 million yen)\nFull-Year Revenue: 5,650,000 million yen (vs. previous guidance +250,000 million yen)\nFull-Year Core Operating Profit: 1,050,000 million yen (vs. previous guidance +140,000 million yen)\nFull-Year Operating Profit: 1,040,000 million yen (vs. previous guidance +140,000 million yen)\nFull-Year Net Income Attributable to Owners of the Parent: 940,000 million yen (vs. previous guidance +170,000 million yen)\nEarnings per Share: 211.07 (vs. previous guidance +~)","jir_category":"","jir_hashtags":"#SumitomoPharma, #EarningsRevision","jir_key_figures":"Revenue: 2,665,000 million yen (interim results)\nFull-year Revenue: 5,650,000 million yen (revised)\nFull-year Core Operating Profit: 1,050,000 million yen (revised)","jir_meta_title":"Sumitomo Pharma Co., Ltd. Upwardly Revises Earnings Guidance | Full-Year Revenue to 565,000 million yen, FX Assumption Revised","jir_meta_description":"Sumitomo Pharma Co., Ltd. has upwardly revised its full-year earnings guidance reflecting second-quarter results. Full-year revenue is now 5,650,000 million yen, core operating profit 1,050,000 million yen, operating profit 1,040,000 million yen, and net income attributable to owners of the parent 940,000 million yen. FX assumption revised to 157 yen\/USD.","jir_og_title":"Sumitomo Pharma Co., Ltd. Upwardly Revises Earnings Guidance | Full-Year Revenue to 565,000 million yen, FX Assumption Revised","jir_og_description":"Sumitomo Pharma Co., Ltd. has revised up its full-year earnings guidance. Key figures include revenue of 5,650,000 million yen, core operating profit of 1,050,000 million yen, operating profit of 1,040,000 million yen, and net income of 940,000 million yen. FX assumption revised.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026\/4\\\",\\\"2026\/7\\\",\\\"2026\/10\\\",\\\"2027\/3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[251000,266490, unresolved, 565000]}]}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Profit Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026\/4\\\",\\\"2026\/7\\\",\\\"2026\/10\\\",\\\"2027\/3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Core Operating Profit\\\",\\\"data\\\":[30000,42123, unresolved, 105000]}]}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Margin Analysis\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026\/4\\\",\\\"2026\/7\\\",\\\"2026\/10\\\",\\\"2027\/3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Core Operating Margin\\\",\\\"data\\\":[%unknown, %unknown, %unknown, %unknown]}]}}\"}]","ir_related_company":7612,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"earnings_guidance","footnotes":""},"sector":[],"importance":[],"class_list":["post-138890","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n